Skip to main content

Table 2 Mortality rates and relative risks for drotrecogin alfa (activated) by enrollment sequence within a site: ADDRESS and PROWESS

From: Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis

 

ADDRESS

PROWESS

Enrollment sequence within a site

Placebo

DrotAA

 

Placebo

DrotAA

 
 

Number

Mortality percentage

Number

Mortality percentage

RR (95% CI)

Number

Mortality percentage

Number

Mortality percentage

RR (95% CI)

1st to 4th patients

727

15.5%

741

20.1%

1.29 (1.04, 1.62)

279

31.5%

280

28.6%

0.91 (0.71, 1.17)

5th to 8th patients

303

17.5%

284

17.3%

0.99 (0.69, 1.40)

179

29.6%

183

24.4%

0.81 (0.58, 1.14)

9th to 12th patients

132

19.7%

142

16.2%

0.82 (0.49, 1.37)

128

25.8%

121

20.7%

0.80 (0.51, 1.26)

>12th patients

135

21.5%

149

14.8%

0.69 (0.42, 1.14)

254

33.5%

266

22.9%

0.69 (0.52, 0.91)

  1. ADDRESS, ADministration of DRotrecogin alfa (activated) in Early Stage Severe Sepsis; CI, confidence interval; DrotAA, drotrecogin alfa (activated); PROWESS, Protein C Worldwide Evaluation in Severe Sepsis; RR, relative risk.